Effect of Physiotherapeutic Interventions on Quality of Life in Patients With Chronic Low Back Pain. (Study 2) (CLBP)
Effects of a Multimodal Intervention Based on the 4 Times T Orthopedic Rehabilitation Decision Tree on the Quality of Life in Non-specific Chronic Low Back Pain.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The purpose of this small RCT is to investigate whether this is a good research design and procedure to measure the effect on QoL, PI and the AROM° in patients with NSP-CLBP. This after following an episode of 6 weeks twice a week physiotherapeutic back rehabilitation according to the 4MTOR®. The results in this research will also be analysed and reported. The research design and procedure will be useful when this small RCT shows that the 4MTOR® can positively influence the QoL,PI and the AROM° with a p value <α = 0.05 in NSP-CLBP patients.
Primary variable is the QoL these are measured using the EQ-5D-3L which consists of the EQ-5D-index and the EQ visual analogue scale (EQ-VAS). The EQ-5D-3L questionnaire is developed by Euroqol Group. Secondary outcome measures are the AROM° of the active trunk flexion and trunk extension measured with a bubble inclinometer. Also, the PI will be scored by the patient during flexion and extension by means of the Verbal Pain Scale scaled 0-10 (VRS). The outcomes will be measured within 12 weeks in all participants. The measurements take place during week 0 the baseline measurement (W0), week 3 the intermediate measurement (W3) week 7 the post measurement (W7) and finally week 12 follow up measurement (W12). All participants were fully informed for the research and agreed by signing the "informed consent" . The research was approved by the Committee of Medical Ethics University Hospital University of Brussels, B.U.N. 143201627110.
Inclusion and exclusion criteria. Participants are included when they meet the following criteria: NSP-CLBP from 12 weeks and longer that are continuously present (with and without recurrent complaints), Age between 20 and 60 years and not yet treated by the 4MTOR®. Participants are excluded when they meet the following criteria: Radiological disturbing pain beyond knee, extremely serious neurological disorder symptoms, overall malaise, spinal cord malignancy, unexplained weight loss, prolonged corticosteroid use, osteoporotic vertebral fracture, spondylitis ankylopoetics, spinal stenosis, rheumatic arthritis, vertebral fracture and severe deformity of the spinal cord.
Recruitment. Patients recruitment: The subjects are recruited from orthopedic hospitals departments in Utrecht the Netherlands. Participants will be asked if they want to refer NSP-CLBP patients for this research and by advertisement in an Dutch-language newspaper (Appendix II). Also, NSP-CLBP patients who applied for physical therapy were asked if they wanted to participate in this research. A call form has been prepared for this purpose (Appendix III). All subjects were asked if they would like to participate in this research. The subjects has been authorized to perform medical physiotherapeutic treatment. This has been done by signing a statement of agreement, as previously stated. Personal data will not be included in this research and are protected by researchers and the Committee of Medical Ethics University Hospital University of Brussels.
Therapist recruitment Experimental intervention group: This physiotherapist has been educated and qualified in the KNGF accredited multimodal intervention according to the 4MTOR®. The physiotherapist has at least 2 years of work experience with the use of the 4MTOR® decision tree.
Therapist recruitment SHAM intervention group: This is Health Care registered physiotherapist and has at least 3 years work experience and is familiar with the KNGF Low Back pain, 2013 guidelines (KNGF_LBP). Both therapists were informed about their work protocol and have agreed to the implementation of the interventions by signing an informed consent.
In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).
The participants in the Sham group (SGR) received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique was applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®.
Primary:
- EQ 5d-5L questionnaire
Secondary:
Thoracolumbo-pelvic flexion, inclinometry Thoracolumbo-pelvic extension, inclinometry (note 5 x for measurement errors) Isolated lumbar flexion, inclinometry Verbal pain score flexion, VRS 0-10 Verbal pain score extension, VRS 0-10
Research design. This research is a one way, Mixed, real experimental design One way design (Independent Groups variables). Mixed Design: Baseline Week 0 - Week 3 - Week 7-Week 12 Within groups: difference in time Between groups: difference between groups.
The sample analysis was performed for the RM-ANOVA using the Gpower © program. The RM-ANOVA power analysis with the following values: Power .95, Alpha 0.50, Sample size effect f2 = .24 resulted in a minimum of 40 participants. 20% will be added on the total N=48 for the possibility of dropouts. The CLBP participants are divided into two groups, each group holding twenty-five participants.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Robbert R.N. Amstel, MSc
- Número de telefone: +31 0611763830
- E-mail: Robbert.Van.Amstel@vub.be
Estude backup de contato
- Nome: Peter P Vaes, PhD
- Número de telefone: +32 +322 477 43 26
- E-mail: pvaes@vub.be
Locais de estudo
-
-
Brussels
-
Jette, Brussels, Bélgica, 1090
- Recrutamento
- Peter Vaes
-
Contato:
- Robbert R.N. van Amstel, MSc
- Número de telefone: +31 0611763830
- E-mail: Robbert.Van.Amstel@vub.be
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Participants are included when they meet the following criteria:
- NSP-CLBP from 12 weeks and longer that are continuously present (with and without recurrent complaints)
- Age between 20 and 60 years
- Not yet treated by the 4MTOR®.
Exclusion Criteria:
Participants are excluded when they meet the following criteria:
- Radiological disturbing pain beyond knee
- Extremely serious neurological disorder symptoms
- Overall malaise
- Spinal cord malignancy
- Unexplained weight loss
- Prolonged corticosteroid use
- Osteoporotic vertebral fracture
- Spondylitis ankylopoetics
- Spinal stenosis
- Rheumatic arthritis
- Vertebral fracture
- Severe deformity of the spinal cord
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição fatorial
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: experimental group (EGR)
Physical therapy intervention. In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises). |
No grupo experimental (EGR), será utilizado o método de tratamento 4MTOR® para lombalgia. Este 4MTOR® utiliza as seguintes etapas em uma árvore de decisão: T1 Testing (Exame Fisioterapêutico), T2 Triggering (Técnicas Manuais), T3 Taping (Fita Elástica) e T4 Training (exercícios de reabilitação médica). Os participantes do SGR receberam uma intervenção fisioterapêutica multimodal simulada como intervenção controle, na qual foi aplicada a técnica Sham. As intervenções consistiram na combinação de intervenções manuais Sham, fitas elásticas de acordo com Kaze32 e Terapia Prática Baseada em Evidências (Apêndice III). O protocolo no SGR segue as etapas semelhantes: Testing, Taping, Triggering e Training como o 4MTOR®. |
|
Comparador Falso: Sham group (SGR)
Physical therapy intervention. The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®. |
No grupo experimental (EGR), será utilizado o método de tratamento 4MTOR® para lombalgia. Este 4MTOR® utiliza as seguintes etapas em uma árvore de decisão: T1 Testing (Exame Fisioterapêutico), T2 Triggering (Técnicas Manuais), T3 Taping (Fita Elástica) e T4 Training (exercícios de reabilitação médica). Os participantes do SGR receberam uma intervenção fisioterapêutica multimodal simulada como intervenção controle, na qual foi aplicada a técnica Sham. As intervenções consistiram na combinação de intervenções manuais Sham, fitas elásticas de acordo com Kaze32 e Terapia Prática Baseada em Evidências (Apêndice III). O protocolo no SGR segue as etapas semelhantes: Testing, Taping, Triggering e Training como o 4MTOR®. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
First measurment: Quality of life, EQ-5D-3L-index
Prazo: Timespad registration: Week 0/baseline measurement (W0), week 3/intermediate measurement (W3)
|
The EQ-5D-3L-index will analyze the participants Quality of life (QoL). Each question in the EQ-5D-3L-index includes one dimension of QoL: mobility, self-care, daily activities, pain/discomfort & anxiety/depression. Each dimension has 3 levels ( having no problems, having some or moderate problems, being unable to do/having extreme problems) and gets a separate score.The scores can be combined in combination with an assessment of the health status they represent, this rating is expressed in weight or utility (1,000 = no problems at all) to (-0,329= extreme problems). Description of the QoL can be transformed into a QoL assessment by means of a formula. These ratings are based on judgments of the general population of all possible combinations of QoL on the different dimensions. An improvement in quality of life will be assumed when p<α=0.05. Within time: W0-W3 Between groups: EGR versus SGR. The results are shown for all variables in a table. |
Timespad registration: Week 0/baseline measurement (W0), week 3/intermediate measurement (W3)
|
|
Second measurment: Quality of life, EQ-5D-3L-index
Prazo: Timespad registration: Week 3/intermediate measurement (W3), week 7/ post measurement (W7)
|
The EQ-5D-3L-index will analyze the participants Quality of life (QoL). Each question in the EQ-5D-3L-index includes one dimension of QoL: mobility, self-care, daily activities, pain/discomfort & anxiety/depression. Each dimension has 3 levels ( having no problems, having some or moderate problems, being unable to do/having extreme problems) and gets a separate score.The scores can be combined in combination with an assessment of the health status they represent, this rating is expressed in weight or utility (1,000 = no problems at all) to (-0,329= extreme problems). Description of the QoL can be transformed into a QoL assessment by means of a formula. These ratings are based on judgments of the general population of all possible combinations of QoL on the different dimensions. An improvement in quality of life will be assumed when p<α=0.05.. Within time: W3-W7 Between groups: EGR versus SGR. The results are shown for all variables in a table. |
Timespad registration: Week 3/intermediate measurement (W3), week 7/ post measurement (W7)
|
|
Third measurment: Quality of life, EQ-5D-3L-index
Prazo: Timespad registration: Week 0/baseline measurement (W0)- Week 7/ post measurement (W7)
|
The EQ-5D-3L-index will analyze the participants Quality of life (QoL). Each question in the EQ-5D-3L-index includes one dimension of QoL: mobility, self-care, daily activities, pain/discomfort & anxiety/depression. Each dimension has 3 levels ( having no problems, having some or moderate problems, being unable to do/having extreme problems) and gets a separate score.The scores can be combined in combination with an assessment of the health status they represent, this rating is expressed in weight or utility (1,000 = no problems at all) to (-0,329= extreme problems). Description of the QoL can be transformed into a QoL assessment by means of a formula. These ratings are based on judgments of the general population of all possible combinations of QoL on the different dimensions. An improvement in quality of life will be assumed when p<α=0.05. Within time: W0-W7 Between groups: EGR versus SGR. The results are shown for all variables in a table. |
Timespad registration: Week 0/baseline measurement (W0)- Week 7/ post measurement (W7)
|
|
Fourth measurment: Quality of life, EQ-5D-3L-index
Prazo: Timespad registration: Week 7/ post measurement (W7) and week 12 follow up measurement (W12)
|
The EQ-5D-3L-index will analyze the participants Quality of life (QoL). Each question in the EQ-5D-3L-index includes one dimension of QoL: mobility, self-care, daily activities, pain/discomfort & anxiety/depression. Each dimension has 3 levels ( having no problems, having some or moderate problems, being unable to do/having extreme problems) and gets a separate score.The scores can be combined in combination with an assessment of the health status they represent, this rating is expressed in weight or utility (1,000 = no problems at all) to (-0,329= extreme problems). Description of the QoL can be transformed into a QoL assessment by means of a formula. These ratings are based on judgments of the general population of all possible combinations of QoL on the different dimensions. An improvement in quality of life will be assumed when p<α=0.05. Within time: W7-W12 Between groups: EGR versus SGR. The results are shown for all variables in a table. |
Timespad registration: Week 7/ post measurement (W7) and week 12 follow up measurement (W12)
|
|
First measurment: EQ- visual analogue scale (VAS)
Prazo: Time Frame: Timespad registration: Week 0/baseline measurement (W0) - week 3/intermediate measurement (W3)
|
The EQ VAS records the respondent's self-rated health on a 20 cm vertical (0-100 score), visual analogue scale with endpoints labelled 'the best health (100) you can imagine' and 'the worst health you can imagine (0) '.
This information can be used as a quantitative measure of health as judged by the individual respondents.
An improvement in quality of life will be assumed when p<α=0.05.
For the EQ-VAS we used the minimum important change (MIC) for VAS 15 points Within time: W0-W3 Between groups: EGR versus SGR.
The results are shown for all variables in a table.
|
Time Frame: Timespad registration: Week 0/baseline measurement (W0) - week 3/intermediate measurement (W3)
|
|
Second measurment: EQ- visual analogue scale (VAS)
Prazo: Timespad registration: Week 3/intermediate measurement (W3), week 7/ post measurement (W7)
|
The EQ VAS records the respondent's self-rated health on a 20 cm vertical (0-100 score), visual analogue scale with endpoints labelled 'the best health (100) you can imagine' and 'the worst health you can imagine (0) '.
This information can be used as a quantitative measure of health as judged by the individual respondents.
An improvement in quality of life will be assumed when p<α=0.05.
For the EQ-VAS we used the minimum important change (MIC) for VAS 15 points Within time: W3-W7 Between groups: EGR versus SGR.
The results are shown for all variables in a table.
|
Timespad registration: Week 3/intermediate measurement (W3), week 7/ post measurement (W7)
|
|
Third measurment: EQ- visual analogue scale (VAS)
Prazo: Timespad registration: Week 0/baseline measurement (W0)- Week 7/ post measurement (W7)
|
The EQ VAS records the respondent's self-rated health on a 20 cm vertical (0-100 score), visual analogue scale with endpoints labelled 'the best health (100) you can imagine' and 'the worst health you can imagine (0) '.
This information can be used as a quantitative measure of health as judged by the individual respondents.
An improvement in quality of life will be assumed when p<α=0.05.
For the EQ-VAS we used the minimum important change (MIC) for VAS 15 points Within time: W0-W7 Between groups: EGR versus SGR.
The results are shown for all variables in a table.
|
Timespad registration: Week 0/baseline measurement (W0)- Week 7/ post measurement (W7)
|
|
Fourth measurment: EQ- visual analogue scale (VAS)
Prazo: Timespad registration: Week 7/ post measurement (W7) and week 12 follow up measurement (W12)
|
The EQ VAS records the respondent's self-rated health on a 20 cm vertical (0-100 score), visual analogue scale with endpoints labelled 'the best health (100) you can imagine' and 'the worst health you can imagine (0) '.
This information can be used as a quantitative measure of health as judged by the individual respondents.
An improvement in quality of life will be assumed when p<α=0.05.
For the EQ-VAS we used the minimum important change (MIC) for VAS 15 points Within time: W7-W12 Between groups: EGR versus SGR.
The results are shown for all variables in a table.
|
Timespad registration: Week 7/ post measurement (W7) and week 12 follow up measurement (W12)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
AROM° thoracolumbar-pelvic flexion (TLPF)
Prazo: Timespad registration: Week 0/baseline measurement (W0), week 3/intermediate measurement (W3), week 7/ post measurement (W7) and week 12 follow up measurement (W12)
|
AROM° Thoracolumbar-pelvic flexion. The inclinometer placed on L1 / T12 with the tape between the inclinometer arcus and was set to 0°. During the test, the investigator kept the inclinometer on L1 / T12 while instructing the subject to bend forward with the arms in hanging position. The changes in our variables will be analyzed within time and between groups. Within time: W0-W3, W0-W7, W3-W7, and W7-W12. Between groups: EGR versus SGR. The results are shown for all variables in a table. The analysis for all variables is significant when p<α=0.05. |
Timespad registration: Week 0/baseline measurement (W0), week 3/intermediate measurement (W3), week 7/ post measurement (W7) and week 12 follow up measurement (W12)
|
|
AROM° thoracolumbar- pelvic extension (TLPE)
Prazo: Timespad registration: Week 0/baseline measurement (W0), week 3/intermediate measurement (W3), week 7/ post measurement (W7) and week 12 follow up measurement (W12)
|
AROM° Thoracolumbar-pelvic extension. The inclinometer placed on L1 / T12 with the tape between the inclinometer arcus and was set to 0 °. During the test, the investigator kept the inclinometer on L1 / T12 while instructing the subject to put his hands on his pelvis and bend backward. The changes in our variables will be analyzed within time and between groups. Within time: W0-W3, W0-W7, W3-W7, and W7-W12. Between groups: EGR versus SGR. The results are shown for all variables in a table. The analysis for all variables is significant when p<α=0.05. |
Timespad registration: Week 0/baseline measurement (W0), week 3/intermediate measurement (W3), week 7/ post measurement (W7) and week 12 follow up measurement (W12)
|
|
AROM° isolated lumbar flexion(ILF)
Prazo: Timespad registration: Week 0/baseline measurement (W0), week 3/intermediate measurement (W3), week 7/ post measurement (W7) and week 12 follow up measurement (W12)
|
AROM° Isolated lumbar flexion test. The inclinometer was moved to labeled S1 / S2 and the inclinometer was set to 0 °. During the test, the investigator held the inclinometer on S1 / S2 while instructing the subject to bend forward. The formula ∑▒〖T12/L1〗 - S1/S2 was used. The changes in our variables will be analyzed within time and between groups. Within time: W0-W3, W0-W7, W3-W7, and W7-W12. Between groups: EGR versus SGR. The results are shown for all variables in a table. The analysis for all variables is significant when p<α=0.05. |
Timespad registration: Week 0/baseline measurement (W0), week 3/intermediate measurement (W3), week 7/ post measurement (W7) and week 12 follow up measurement (W12)
|
|
Pain intensity flexion (0-10)
Prazo: Timespad registration: Week 0/baseline measurement (W0), week 3/intermediate measurement (W3), week 7/ post measurement (W7) and week 12 follow up measurement (W12)
|
Before the participant gave a PI number to the active flexion or extension, the VRS scale was shown. Thereafter the movement was performed as described in the protocol. After completing the active flexion or extension, the participant gave a VRS score regarding the PI. The changes in our variables will be analyzed within time and between groups. Within time: W0-W3, W0-W7, W3-W7, and W7-W12. Between groups: EGR versus SGR. The results are shown for all variables in a table. The analysis for all variables is significant when p<α=0.05. |
Timespad registration: Week 0/baseline measurement (W0), week 3/intermediate measurement (W3), week 7/ post measurement (W7) and week 12 follow up measurement (W12)
|
|
Pain intensity extension (0-10)
Prazo: Timespad registration: Week 0/baseline measurement (W0), week 3/intermediate measurement (W3), week 7/ post measurement (W7) and week 12 follow up measurement (W12)
|
. Before the participant gave a PI number to the active flexion or extension, the VRS scale was shown. Thereafter the movement was performed as described in the protocol. After completing the active flexion or extension, the participant gave a VRS score regarding the PI. The changes in our variables will be analyzed within time and between groups. Within time: W0-W3, W0-W7, W3-W7, and W7-W12. Between groups: EGR versus SGR. The results are shown for all variables in a table. The analysis for all variables is significant when p<α=0.05. |
Timespad registration: Week 0/baseline measurement (W0), week 3/intermediate measurement (W3), week 7/ post measurement (W7) and week 12 follow up measurement (W12)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Peter P Vaes, PhD, University of Brussels, faculty of Rehabilitation science and physical therapy, faculty of Pharmacy and medicine, Brussels, Belgium
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- EBP4MTOR02
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Qualidade de vida
-
Aalborg UniversityConcluídoUltrassonografia Point of Care (POCUS)Dinamarca
-
Sorbonne UniversityAalborg UniversityRecrutamentoUltrassom Point of CareFrança
-
Asociacion Española Primera en SaludIntensive Care Unit Pasteur HospitalConcluídoUltrassom Point of CareUruguai
-
Aga Khan UniversityThe Hospital for Sick Children; Grand Challenges CanadaDesconhecidoUltrassom Point of CarePaquistão
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...ConcluídoTransgênero, HIV Continuum of CareEstados Unidos
-
Thomas Jefferson UniversityRecrutamentoVentilação mecânica | Ultrassom Point of Care | Oxigenação | Ventilação Manual | Distúrbio da função cardíaca pós-operatórioEstados Unidos
-
Hospital for Special Surgery, New YorkRecrutamentoPeptídeo 1 semelhante ao glucagon | Ultrassom Gástrico | Ultrassom Point of CareEstados Unidos, Canadá
-
Queens College, The City University of New YorkRecrutamentoPublicação de artigos submetidos ao American Journal of Public HealthEstados Unidos
-
Tanta UniversityDesconhecidoDiâmetro da bainha do nervo óptico | Ultrassom Point of CareEgito
-
Johann Wolfgang Goethe University HospitalConcluídoFormação de Coágulos e Agregação de Plaquetas em Testes Point of CareAlemanha
Ensaios clínicos em Intervenção fisioterapêutica
-
University of TurkuDesconhecidoSaudável | Comportamento de saúdeFinlândia
-
Munich Municipal HospitalTechnical University of Munich; University of RegensburgDesconhecidoInfarto CerebralAlemanha
-
Henry Ford Health SystemBlue Cross Blue Shield of Michigan FoundationConcluído
-
Northwestern UniversityEmory UniversityConcluídoAfasia Progressiva Primária | Esgotamento do cuidadorEstados Unidos
-
Rhode Island HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development...ConcluídoCyberbullyingEstados Unidos
-
University of VirginiaConcluídoLesão da medula espinal | Úlceras de pressãoEstados Unidos
-
Charles G. ProberStanford University; Heidelberg University; University of Stellenbosch; University...ConcluídoAleitamento Materno Exclusivo | Práticas de alimentação infantilÁfrica do Sul
-
University of Alabama, TuscaloosaNational Institute of Nursing Research (NINR)ConcluídoDor | Cuidado paliativo | Distúrbios da Retenção Cognitiva | Outra doença crônicaEstados Unidos
-
Brigham and Women's HospitalUniversity of Colorado, DenverConcluídoDiabetes Mellitus GestacionalEstados Unidos
-
LuciLabCentre de Recherche de l'Institut Universitaire de Geriatrie de Montreal; Sojecci...ConcluídoComportamento de risco | Declínio CognitivoCanadá